欧康维视生物-B公告，集团自主研发产品OT-802(盐酸毛果芸香碱滴眼液)III期临床试验授权近日获得国 家药品监督管理局药品审评中心批准。OT-802用于治疗老视，临床前研究表明其具有起效快、安全性 高的特点。集团将尽快启动OT-802III期临床试验。 ...

Financial Performance - In 2024, the company's revenue reached RMB 417.3 million, representing a year-on-year growth of 69.4%[8] - The company's revenue for the fiscal year 2024 reached RMB 417,307 thousand, a significant increase of 69.3% compared to RMB 246,367 thousand in 2023[12] - The company achieved a revenue of RMB 417.3 million, representing a year-on-year growth of 69.4%, with a gross margin of approximately 53.9%[17] - Ophthalmic product sales revenue surged by 87.8%, contributing RMB 384.3 million in 2024 compared to RMB 204.7 million in 2023[41] - Gross profit for 2024 was RMB 225,065 thousand, representing a gross margin of approximately 54%[12] - Gross profit rose by 55.9% from RMB 144.4 million in 2023 to RMB 225.1 million in 2024, aligning with revenue growth[43] - The adjusted net loss for the reporting period was RMB 183.6 million, a decrease of 24.5% year-on-year, primarily due to increased revenue and gross profit from ophthalmic products[17] - The net loss attributable to the company for 2024 was RMB 268,274 thousand, an improvement from a net loss of RMB 379,787 thousand in 2023[13] - The adjusted net loss for 2024 was RMB 183,642 thousand, compared to RMB 243,237 thousand in 2023, indicating a trend towards reduced losses[13] Product Development and Innovation - The core product, OT-401, saw significant sales growth after being included in the national medical insurance catalog, further expanding market coverage[8] - The company’s innovative drug, OT-1001, was approved for market launch in 2024, with OT-702 and OT-502 having submitted NDA applications[7] - The new drug, Zhiweitai® (0.24% cetirizine eye drops), was approved for commercialization in September 2024, with two additional innovative products entering the registration phase[17] - The pipeline includes three products in Phase III clinical trials and two innovative drugs in the commercialization registration phase[17] - The NDA for OT-502 (DEXYCU®) was accepted by the National Medical Products Administration in September 2024, with expectations for commercialization approval within the year[25] - OT-702 (博優景®) completed Phase III clinical trials in April 2024, showing significant improvement in best-corrected visual acuity compared to baseline, and the BLA was accepted in July 2024[23] Strategic Partnerships and Collaborations - The company established a long-term strategic relationship with Alcon Group, acquiring and licensing a total of 8 products, 7 of which are commercially validated with stable sales foundations[9] - The partnership with Alcon is expected to enhance the company's brand recognition and influence in the international ophthalmic field[9] - The Alcon transaction granted the company rights to eight products in China, including seven commercialized products and one in clinical development, enhancing its market position[29] - The company entered into a manufacturing and supply agreement with Alcon Pharma to purchase transferred products for commercialization in China[190] Operational Efficiency and Management - The company is committed to enhancing its commercialization capabilities and optimizing sales team efficiency, which is expected to lead to significant revenue growth in the short term[9] - The company’s Suzhou factory optimized production processes and management levels, achieving commercial batch production of its own products and providing complex ophthalmic formulation CDMO services[8] - The company plans to optimize production and supply chain management, focusing on stable supply and product quality in 2025[32] - The company completed 11 batches of commercial production during the reporting period, ensuring a stable and efficient supply of products[30] Research and Development - Research and development expenses decreased to RMB 113,935 thousand in 2024 from RMB 123,768 thousand in 2023, indicating a focus on cost management[12] - Continuous investment in R&D is prioritized to maintain technological leadership and explore new treatment areas[37] - The company has established a comprehensive ophthalmic drug product line with 34 drug assets, including 21 products in the commercialization stage[17] Market Expansion and Future Outlook - The company aims to continue improving its commercialization system and sales efficiency to ensure sustained revenue growth in 2025[10] - The company plans to leverage international cooperation to enhance its overall strength and move towards becoming a global leader in ophthalmic innovative drugs[10] - The company plans to accelerate new product development and commercialization, aiming for at least one NDA approval in 2025[31] - The company is focused on addressing the significant unmet needs in China's ophthalmic healthcare market[17] Corporate Governance and Management Structure - The company has a commitment to high levels of corporate governance to protect shareholder interests and enhance corporate value[93] - The board consists of two executive directors, three non-executive directors, and three independent non-executive directors, ensuring compliance with listing rules[99] - The company has established effective mechanisms to support an independent board and independent viewpoints, ensuring good corporate governance[107] - The company has a gender diversity policy in place, aiming to maintain a balanced representation of female members on the board[104] Shareholder Communication and Relations - The company has adopted a shareholder communication policy to enhance investor relations and ensure timely disclosure of information to shareholders and potential investors[148] - The company emphasizes the importance of effective communication with shareholders to strengthen investor relations and provide insights into its business and strategies[147] - The company maintains regular communication with shareholders to ensure the quality and effectiveness of information disclosure[178] Risk Management - The company has established a risk management manual clarifying responsibilities and processes for risk management across departments[141] - The board has reviewed and confirmed the effectiveness of the risk management and internal control systems as of December 31, 2024, ensuring adequate protection for stakeholders[142] - The group faces risks related to the successful completion of clinical trials and obtaining regulatory approvals for new drug candidates[167] Employee and Organizational Development - The total employee count increased to 489 as of December 31, 2024, up from 444 in the previous year[69] - Employee training programs are provided to ensure compliance with company policies and procedures, with a focus on both formal and on-the-job training[69] - The company encourages all directors to attend relevant training courses, with costs covered by the company[109]

Financial Performance - The company achieved revenue of RMB 417.3 million for the year ended December 31, 2024, representing a year-on-year growth of 69.4%[3] - The adjusted net loss narrowed to RMB 183.6 million for the year ended December 31, 2024, a significant decrease of RMB 59.6 million compared to RMB 243.2 million for the previous year[4] - The gross profit margin for the company was approximately 53.9% during the reporting period[3] - The company reported a significant increase in revenue from the sales of ophthalmic products, including Youshiying®, Shilida®, and Shilijia®[4] - The company achieved total revenue of RMB 417.3 million, representing a year-on-year growth of 69.4%[17] - The company recorded a loss of RMB 268.3 million, a decrease of RMB 111.5 million compared to a loss of RMB 379.8 million for the year ending December 31, 2023[39] - The adjusted net loss for the year, which excludes non-cash items, was RMB 183.6 million for 2024, compared to RMB 243.2 million for 2023, reflecting an improvement in operational performance[42] - The company reported a net loss of RMB 268.3 million for the year, an improvement from a net loss of RMB 379.8 million in 2023, indicating a reduction in losses by 29.3%[60] Product Development and Approvals - The core product, Youshiying® (fluocinolone acetonide intravitreal implant), has been officially approved and included in the national medical insurance catalog[3] - The innovative drug Zhiweitai® (0.24% cetirizine eye drops) has been approved for commercialization[3] - The BLA for OT-702 was accepted by the CDE in July 2024, and the NDA for OT-502 (dexamethasone implant) was accepted by the National Medical Products Administration in September 2024[3] - The new drug, Zhiweitai® (0.24% cetirizine eye drops), was approved for commercialization in September 2024, with two additional innovative products entering the registration phase[8] - The company has established a comprehensive ophthalmic product line with 34 drug assets, including 21 products in commercialization and three in Phase III clinical trials[6] - The innovative drug pipeline includes treatments for various ophthalmic conditions, such as diabetic macular edema and allergic conjunctivitis[6] - The company has three products in Phase III clinical trials and two products in the commercialization registration phase, maintaining its position as a leading innovative ophthalmic pharmaceutical company in China[10] Strategic Collaborations and Market Expansion - The strategic collaboration with Alcon contributed to revenue growth through synergies[4] - The introduction of multiple eye drop products from Alcon Group has enriched the product portfolio and expanded market share[8] - The company holds commercial rights for several products across Greater China, South Korea, and Southeast Asia, enhancing its market presence[6] - The company plans to expand its international market presence and explore partnerships to enhance global reach, particularly through licensing innovative products[25] - The company has established a manufacturing and supply agreement with Alcon Pharma as of August 12, 2024[111] - The company has entered into a licensing agreement with Alcon Pharma for the exclusive development and commercialization of pipeline products for dry eye treatment in China[111] Research and Development - R&D expenses amounted to RMB 113.9 million, indicating continued investment in the development of the pipeline[8] - Continuous investment in R&D is prioritized to maintain technological leadership and explore new treatment areas[26] - Research and development expenses decreased by 7.9% from RMB 123.8 million in 2023 to RMB 113.9 million in 2024, attributed to reduced third-party contracting costs[34] Operational Efficiency and Supply Chain - Commercial production of four products has commenced, ensuring a stable and efficient supply for the company's commercialization pipeline[3] - The company completed 11 batches of commercial production during the reporting period, ensuring a stable supply of high-quality ophthalmic products[19] - The company aims to optimize production and supply chain management, focusing on stable supply and product quality in its Suzhou factory in 2025[21] Financial Stability and Assets - The company has approximately RMB 769.2 million in bank balances and cash as of December 31, 2024[5] - Total current assets decreased to RMB 978.8 million in 2024 from RMB 1,205.6 million in 2023, while total non-current assets increased to RMB 2,995.0 million from RMB 2,065.4 million[43] - The company's cash and cash equivalents as of December 31, 2024, were RMB 729.2 million, down from RMB 842.8 million in 2023[48] - The company had loans amounting to RMB 16.5 million as of December 31, 2024, significantly reduced from RMB 120.0 million in 2023[49] - The total liabilities decreased to RMB 200.2 million in 2024 from RMB 351.0 million in 2023, indicating improved financial stability[43] Shareholder and Corporate Governance - Alcon became the company's major shareholder after a transaction, holding 139,159,664 shares, which is 16.99% of the total issued shares as of the transaction date[55] - The company achieved gender diversity on its board with the appointment of Dr. Xie Qin as a non-executive director on January 16, 2025[92] - The board of directors did not recommend a final dividend for the year ending December 31, 2024, consistent with the previous year[102] Miscellaneous - The company acknowledges the ongoing support and contributions from shareholders, management, employees, business partners, and customers[108] - The audit committee reviewed the group's annual performance for the year ending December 31, 2024, and recommended it for board approval[105] - The annual report for the year ending December 31, 2024, will be published and sent to shareholders in due course[107] - The company is in the process of arranging the timing for the annual general meeting in accordance with listing rules[106]

Ocumension Therapeutics 歐康維視生物 INTERIM REPORT 2024 中期報告 Ocumension Therapeutics 歐康維視生物 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock code 股份代號 : 1477 Virtus et Lumen 勇氣和光明 2024 INTERIM REPORT 中期報告 | --- | --- | --- | --- | --- | |-------|-------|------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 公司資料 目錄 | | 2 | | | | 財務概要 公司概覽 | | 4 | | | | 管理層討論與分析 | | 5 6 | | | | 業務回顧 | | 6 | | | | 財務回顧 | | 10 ...

Financial Performance - The company achieved revenue of RMB 167.6 million for the six months ended June 30, 2024, representing a 61.6% increase compared to RMB 103.7 million for the same period in 2023[2] - The adjusted net loss narrowed to RMB 100.8 million for the six months ended June 30, 2024, down from RMB 125.9 million for the same period in 2023, primarily due to increased revenue from ophthalmic products[3] - The company recorded a loss of RMB 151.3 million for the six months ended June 30, 2024, an improvement from a loss of RMB 208.4 million in the same period last year[32] - The company reported a loss before tax of RMB 151,076 thousand for the period, compared to a loss of RMB 208,263 thousand in the previous period, representing a 27.4% improvement[46] - Basic and diluted loss per share was RMB 0.23, an improvement from RMB 0.32 in the previous period[47] Revenue Breakdown - Revenue from ophthalmic products sales surged by 78.1% to RMB 150.0 million, up from RMB 84.2 million year-on-year[20] - Revenue from contract development and manufacturing (CDMO) services rose significantly from RMB 0.3 million to RMB 3.5 million[20] - Total revenue from external customers amounted to RMB 165,456,000, an increase from RMB 102,401,000 for the six months ended June 30, 2023[61] Product Development and Clinical Trials - The core product, Yushi Ying® (fluocinolone acetonide intravitreal implant), has seen rapid growth following its inclusion in the updated National Medical Insurance Drug List, with nearly 2,000 injections completed in the first half of 2024[3] - The company completed Phase III clinical trials for OT-702 (similar to EYLEA®) with positive results, and the biological product license application was accepted by CDE in July 2024[2] - The innovative drug OT-202 (tyrosine kinase inhibitor) for dry eye disease achieved its primary clinical endpoint in Phase II trials and is expected to enter Phase III trials in the second half of the year[8] - The company has three products in Phase III clinical trials and three in the commercialization registration phase, covering major anterior and posterior eye diseases[7] Research and Development - R&D expenses amounted to RMB 58.7 million, a decrease of 19.7% compared to the same period in 2023, indicating a focus on advancing the pipeline[6] - The company allocated approximately HKD 1,646.41 million for various purposes, with 12% used for OT-401 development costs and ongoing R&D activities[75] - Ongoing R&D activities for other candidate drugs, including OT-101, OT-301, and OT-502, have been allocated HKD 562.42 million, representing 34.16% of total funds[75] Market Expansion and Strategy - The company aims to provide world-class drug solutions to meet the significant unmet needs in China's ophthalmic healthcare market[4] - The company is exploring international market expansion and partnerships to bring its quality products to global patients[18] - Alimera plans to expand its market presence in Asia, targeting a 30% increase in market share by the end of 2025[82] Operational Efficiency - The company is committed to optimizing production and supply chain management to enhance efficiency and reduce costs[14] - The company is implementing new strategies to improve operational efficiency, aiming for a 15% reduction in costs by 2025[83] Cash and Assets - The company has a cash balance of approximately RMB 972.9 million as of June 30, 2024[3] - The company's cash and cash equivalents stood at RMB 862.9 million as of June 30, 2024, an increase from RMB 842.8 million at the end of 2023[37] - As of June 30, 2024, total assets amounted to RMB 3,026,145,000, a decrease from RMB 3,270,999,000 as of December 31, 2023[35] Corporate Governance - The company has adopted a corporate governance code to enhance transparency and accountability since its listing on July 10, 2020[72] - The independent auditor has reviewed the interim financial statements for the six months ending June 30, 2024, confirming compliance with applicable accounting standards[80]

Financial Performance - In 2023, the company's annual sales revenue reached 246 million, an increase of 55.0% compared to the previous year[8]. - The company's revenue for the fiscal year ended December 31, 2023, was RMB 246,367,000, an increase of 55% compared to RMB 158,957,000 in 2022[12]. - Gross profit for 2023 was RMB 144,365,000, representing a gross margin of approximately 58.5%[12]. - The net loss for the year was RMB 379,787,000, a slight improvement from a net loss of RMB 402,643,000 in 2022[13]. - The company recorded a total comprehensive income of RMB 27.5 million for the year ended December 31, 2023, compared to a total comprehensive expense of RMB 580.0 million for the previous year[40]. - Cash and bank balances as of December 31, 2023, were approximately RMB 1,053.8 million[41]. - The company reported other income of RMB 23,203,000 in 2023, down from RMB 35,654,000 in 2022[12]. - The financial cost for the year was RMB 1,325,000, a decrease from RMB 1,793,000 in 2022, indicating a reduction of approximately 26.1%[12]. - The company recorded short-term loans of RMB 120.0 million as of December 31, 2023, compared to none as of December 31, 2022, with fixed interest rates of 3.0% and 3.1%[64]. - The company has not declared or paid any dividends on ordinary or preferred shares, and any future dividend payments will depend on various factors including profitability and capital needs[185]. Research and Development - The company successfully completed the NDA submission for ZERVIATE® (OT-1001), which is expected to be approved soon for treating allergic conjunctivitis in children[7]. - The company completed patient enrollment for three Phase III clinical trials for OT-101, OT-702, and DEXYCU® (OT-502), achieving significant milestones for future registration submissions[7]. - The company is set to announce results for the Phase II clinical trial of OT-202 in Q1 2024, continuing its leadership in ophthalmic research and development[7]. - The company has a comprehensive ophthalmic product line with 25 drug assets, including five products in Phase III clinical trials, addressing major anterior and posterior eye diseases[15]. - OT-1001 (ZERVIATE®) for allergic conjunctivitis has received NDA acceptance from the National Medical Products Administration and is included in the priority review and approval process, expected to be approved soon[21]. - OT-101 (0.01% atropine sulfate eye drops) has completed patient enrollment of 678 in a global Phase III clinical trial[19]. - OT-502 (DEXYCU®) has completed real-world studies with 263 patients and is expected to submit NDA this year after completing enrollment of 300 patients in Phase III trials[26][27]. - OT-702 (a biosimilar to Aflibercept) has successfully completed patient enrollment for Phase III clinical trials and is expected to submit NDA this year[23][24]. - The company plans to initiate Phase III clinical trials for OT-202 in 2023[30]. - The company aims to continue advancing its Phase III clinical trials throughout the year[20]. Market Expansion and Product Development - The company expanded its market presence by obtaining approval for ILUVIEN® (OT-703) in Hong Kong, marking its first listing outside mainland China[7]. - The company established a national academic network for the launch of its product, Yushiying®, which successfully entered the new national medical insurance drug list, setting the stage for rapid sales growth in 2024[8]. - Sales of ophthalmic products rose by 88.1% to RMB 204.7 million, up from RMB 108.8 million in the previous year[43]. - The new drug Yushiying (fluocinolone acetonide intravitreal implant) has been included in the latest National Medical Insurance Drug List, effective January 1, 2024, significantly reducing patient payment burdens[36]. - The company aims to adapt to market changes and continue rapid development, focusing on creating value for shareholders in its sixth year of operation[10]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[100]. - A strategic acquisition is in progress, aimed at enhancing the company's technological capabilities and product offerings[100]. - The company has invested HKD 200 million in R&D for new technologies, representing a 20% increase in R&D spending compared to last year[100]. Workforce and Management - The workforce increased from 398 employees at the end of 2022 to 444 employees by December 31, 2023, reflecting business expansion[10]. - The total employee compensation cost for the year ended December 31, 2023, was RMB 314.6 million, down from RMB 382.1 million in 2022[75]. - The management team has been strengthened with the appointment of a new CFO, who has extensive experience in investment banking and financial management[98]. - Liu Hongying appointed as Chief Manufacturing Officer in January 2023, overseeing the construction and operation of the Suzhou factory and production of real estate products[101]. - Shen Bo appointed as Chief Medical Officer starting January 2024, leading the group's clinical research and development efforts[101]. Corporate Governance and Compliance - The company has adopted a corporate governance code and believes it has fully complied with its provisions for the year ending December 31, 2023[109]. - The board consists of at least three independent non-executive directors, with one possessing appropriate professional qualifications in accounting or related financial management knowledge[116]. - The company has established three board committees: Audit Committee, Remuneration Committee, and Nomination Committee to oversee specific matters[112]. - The company has implemented measures to promote gender diversity at all levels, including management[125]. - The board's composition is deemed reasonable, with diverse experiences and skills that maintain high operational standards[119]. - The company has established effective mechanisms to support an independent board and independent viewpoints[126]. - The company has implemented a compliance window for employees to report compliance inquiries and issues anonymously[169]. - The board of directors confirmed that the risk management and internal control systems were effective and sufficient to protect stakeholders' interests as of December 31, 2023[170]. Strategic Vision and Future Outlook - The company is a Chinese ophthalmic pharmaceutical platform focused on identifying, developing, and commercializing innovative ophthalmic therapies to meet the significant demand gap in China's eye care market[194]. - The company’s vision is to provide world-class drug solutions to address the substantial unmet needs in Chinese ophthalmic healthcare[194]. - The company aims to improve operational efficiency, targeting a 10% reduction in operational costs by the end of the fiscal year[100]. - The company anticipates NDA approval for OT-1001 within the year and aims to advance clinical progress for self-developed products like OT-101 and OT-202[39]. - The company is committed to social responsibility, employee welfare, and environmental protection, aiming for sustainable growth through resource and emission management[197].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告包含涉及風險及不確定因素的前瞻性陳述。歷史事實陳述以外的所有陳述均屬前瞻性陳 述。該等陳述涉及已知及未知的風險、不確定因素及其他因素，當中部分因素屬本公司控制範 圍以外，可能會導致實際業績、表現或成果與前瞻性陳述所明示或暗示者大相徑庭。 閣下不 應依賴前瞻性陳述作為未來事件的預測。本公司並無責任更新或修改任何前瞻性陳述（不論因 新增資料、未來事件或其他方面）。 Ocumension Therapeutics 歐康維視生物 （於開曼群島註冊成立的有限公司） （股份代號：1477） 截至2023年12月31日止年度全年業績公告 本公司董事會欣然宣佈，本集團截至2023年12月31日止年度的經審核綜合全年業 績連同截至2022年12月31日止年度的比較數字如下。本集團於報告期間的綜合財 務報表已獲審核委員會審閱及本公司核數師德勤•關黃陳方會計師行審核。 在本公告內，「我們」指本公司及本集團（如文義另有所 ...

Ocumension Therapeutics 歐康維視生物 Ocumension Therapeutics 歐康維視生物 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock code 股份代號 : 1477 2023 INTERIM REPORT 中期報告 INTERIM REPORT 2023 中期報告Virtus et Lumen 勇氣和光明 目錄 公司資料 2 財務概要 4 公司概覽 5 | --- | --- | |------------------|-------| | | | | 管理層討論及分析 | 6 | | 業務回顧 | 6 | | 財務回顧 | 10 | 其他資料 18 32 | --- | |------------------------------| | | | 簡明綜合財務報表審閱報告 | | 簡明綜合損益及其他全面收益表 | | 簡明綜合財務狀況表 | | 簡明綜合權益變動表 | | 簡明綜合現金流量表 | | 簡明綜合財務報表附註 | | 釋義及縮略詞 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告包含涉及風險及不確定因素的前瞻性陳述。歷史事實陳述以外的所有陳述均屬前瞻性陳 述。該等陳述涉及已知及未知的風險、不確定因素及其他因素，當中部分因素屬本公司控制範 圍以外，可能會導致實際業績、表現或成果與前瞻性陳述所明示或暗示者大相徑庭。 閣下不 應依賴前瞻性陳述作為未來事件的預測。本公司並無責任更新或修改任何前瞻性陳述（不論因 新增資料、未來事件或其他方面）。 Ocumension Therapeutics 歐康維視生物 （於開曼群島註冊成立的有限公司） （股份代號：1477） 截至2023年6月30日止六個月 中期業績公告 董事會欣然宣佈，本集團截至2023年6月30日止六個月的未經審核簡明綜合中期 業績連同2022年同期的比較數字如下。中期業績已獲審核委員會及本公司核數師 德勤‧關黃陳方會計師行審閱。 在本公告內，「我們」指本公司及本集團（如文義另有所指）。本公告內若干金額及 百分比數字已經約 ...

Ocumension Therapeutics 歐康維視生物 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock code 股份代號 : 1477 Virtus et Lumen 勇氣 和光明 2022 年度報告 ANNUAL REPORT | --- | |----------| | | | 公司資料 | | 主席致辭 | | 財務概要 | 2 4 6 管理層討論及分析 8 董事及高級管理層概覽 22 企業管治報告 29 董事會報告 46 獨立核數師報告 73 綜合損益及其他全面收益表 78 綜合財務狀況表 79 綜合權益變動表 80 綜合現金流量表 81 綜合財務報表附註 83 釋義及縮略詞 155 01 公司資料 董事會 執行董事 Ye LIU先生（首席執行官） 胡兆鵬博士 非執行董事 Lian Yong CHEN博士（董事會主席） Wei LI博士 曹彥凌先生 王雨濛女士 獨立非執行董事 胡定旭先生 黃翼然先生 何連明先生（於2022年3月30日離世） 張振宇先生（於2022年4月8日 ...